Pictet Asset Management Holding SA Sells 191,528 Shares of Albemarle Corporation $ALB

Pictet Asset Management Holding SA reduced its stake in shares of Albemarle Corporation (NYSE:ALB – Free Report) by 89.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 23,390 shares of the specialty chemicals company’s stock after selling 191,528 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Albemarle were worth $2,474,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Asset Dedication LLC increased its holdings in shares of Albemarle by 358.1% during the third quarter. Asset Dedication LLC now owns 1,388 shares of the specialty chemicals company’s stock worth $147,000 after buying an additional 1,085 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Albemarle by 6.8% in the third quarter. Alps Advisors Inc. now owns 272,110 shares of the specialty chemicals company’s stock valued at $31,626,000 after acquiring an additional 17,359 shares during the last quarter. CenterBook Partners LP grew its position in shares of Albemarle by 38.7% during the 3rd quarter. CenterBook Partners LP now owns 23,021 shares of the specialty chemicals company’s stock worth $2,435,000 after buying an additional 6,425 shares during the period. International Assets Investment Management LLC raised its position in shares of Albemarle by 182.0% during the 3rd quarter. International Assets Investment Management LLC now owns 7,104 shares of the specialty chemicals company’s stock valued at $751,000 after acquiring an additional 4,585 shares during the last quarter. Finally, Heritage Family Offices LLP acquired a new position in shares of Albemarle in the 3rd quarter valued at $126,000. Institutional investors and hedge funds own 92.87% of the company’s stock.

Albemarle Trading Down 1.3%

Shares of ALB stock traded down $1.23 on Friday, hitting $93.62. The stock had a trading volume of 1,177,544 shares, compared to its average volume of 2,510,124. The company has a current ratio of 2.34, a quick ratio of 1.57 and a debt-to-equity ratio of 0.21. Albemarle Corporation has a twelve month low of $89.77 and a twelve month high of $221.00. The company has a fifty day moving average price of $103.61 and a two-hundred day moving average price of $145.56. The firm has a market cap of $11.05 billion, a P/E ratio of 22.61, a PEG ratio of 0.59 and a beta of 1.34.

Albemarle (NYSE:ALB – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The specialty chemicals company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.52 billion. Albemarle had a return on equity of 14.91% and a net margin of 10.40%. The firm’s revenue was up 18.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.19) EPS. As a group, analysts forecast that Albemarle Corporation will post 10.64 earnings per share for the current fiscal year.

Albemarle Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, December 18th will be given a dividend of $0.41 per share. The ex-dividend date of this dividend is Friday, December 18th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 1.8%. Albemarle’s dividend payout ratio (DPR) is currently 39.61%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Bank of America decreased their price objective on Albemarle from $131.00 to $120.00 in a research note on Thursday. Scotiabank dropped their price objective on Albemarle from $190.00 to $165.00 and set a “sector outperform” rating for the company in a report on Monday, November 9th. UBS Group cut their target price on Albemarle from $150.00 to $137.00 and set a “buy” rating on the stock in a research note on Monday, November 9th. Truist Financial restated a “buy” rating and set a $170.00 target price (down from $185.00) on shares of Albemarle in a report on Friday, November 6th. Finally, HSBC decreased their target price on Albemarle from $230.00 to $170.00 and set a “buy” rating for the company in a research report on Thursday, July 23rd. Fifteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $152.63.

Check Out Our Latest Report on ALB

Albemarle Company Profile

(Free Report)

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.

Featured Stories

Want to see what other hedge funds are holding ALB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albemarle Corporation (NYSE:ALB – Free Report).

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.